Stephens analyst Sudan Loganathan has maintained their bullish stance on CCCC stock, giving a Buy rating on September 3.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sudan Loganathan has given his Buy rating due to a combination of factors that highlight the potential growth and competitive edge of C4 Therapeutics. The company has made significant progress with its TORPEDO platform, which is designed to degrade disease-causing proteins, a promising approach in the treatment of multiple myeloma. The advancement of key partnerships, such as with Biogen, underscores the external validation and potential of their technology.
Additionally, C4 Therapeutics’ lead asset, cemsidomide, has shown consistent response rates and a broader therapeutic dosing window compared to competitors. This positions it as a strong contender in the multiple myeloma treatment landscape. The upcoming clinical readouts are expected to further validate the company’s strategy and reinforce the view that the current stock levels offer an attractive entry point with significant upside potential.
In another report released on September 3, Guggenheim also initiated coverage with a Buy rating on the stock with a $8.00 price target.